When will Eltrombopag/Eltrombopag be included in medical insurance? Changes in medical insurance policies that patients need to know

Eltrombopag/ Eltrombopag is a drug used to treat chronic idiopathic thrombocytopenia (ITP) and other diseases related to low platelets. The drug helps patients increase platelet counts and reduce the risk of bleeding by stimulating platelet production. Eltrombopag has become an important treatment option due to its remarkable efficacy in many patients with thrombocytopenia. However, the high price of eltrombopag makes it unaffordable for many patients, so whether it is included in medical insurance has become an important issue for patients.

According to domestic and foreign policy changes, Eltrombopag has gradually entered the field of medical insurance negotiations. In China, Eltrombopag has been involved in medical insurance negotiations many times, but failed to successfully enter the medical insurance directory in the first few rounds of negotiations. With further research on the efficacy and safety of eltrombopag and increasing patient demand, more and more clinical data support its important role in the treatment of thrombocytopenia. Therefore, the issue of medical insurance inclusion of eltrombopag has become the focus of attention of the medical industry and policy makers.

Finally, Eltrombopag passed the negotiation on China’s medical insurance catalog in 2019 and was successfully included in the medical insurance in 2020. This change means that patients who need eltrombopag treatment can enjoy more medical insurance reimbursement during the treatment process and reduce their financial burden. After being included in medical insurance, the price of Eltrombopag has dropped significantly compared with the original retail price on the market, greatly improving the accessibility of the drug.

After Eltrombopag is included in medical insurance, its indications are mainly focused on chronic idiopathic thrombocytopenia, severe aplastic anemia and other related diseases caused by platelet deficiency. When patients receive eltrombopag treatment, part of the cost can be reimbursed through medical insurance, thereby reducing financial pressure. It should be noted that eltrombopag should be used according to the guidance of a doctor and in strict accordance with the drug instructions to ensure efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB06210